Although many emerging pharmacological interventions have been studied, such as testosterone supplementation [13], selective androgen receptor modulators [14], myostatin inhibitors [15], and anti-obesity drugs [5, 6], there are no approved drugs for the treatment of SO in the elderly. Here, AR is linked to obesity due to melanocortin 4 receptor deficiency.